Expert: Diabetes Drug Should Be Pulled Over Heart Risks

WASHINGTON (AP) - A federal scientist says the widely used diabetes drug Avandia should be pulled from the market because of heart risks.

The Food and Drug Administration scientist says those risks, combined with no unique short-term benefits for diabetics, fail to justify keeping Avandia on the market.

A recent study by Dr. Steven Nissen of the Cleveland Clinic pooled results of a number of studies to suggest that Avandia raised the risk of heart attacks by 43 percent and possibly heart-related deaths.

At a meeting today, the FDA is seeking input from outside experts on what to do about the drug.

Drug maker GlaxoSmithKline says its own data show no increase in heart risks with Avandia.